Experience of using alirocumab in patients with very high cardiovascular risk in the Republic of Buryatia

The article presents the experience of using alirocumab, an inhibitor of protein subtilisin kexin complex 9 (iRSK-9), in patients with high cardiovascular risk and severe hyperlipidemia in the Republic of Buryatia. The efficacy and safety of biological therapy were assessed in 11 patients with very high cardiovascular risk (average age 60.0±6.4 years), an assessment was based on clinical and laboratory indicators - the occurrence of repeated cardiovascular accidents, achievement of the target low-density lipoprotein-cholesterol, and the development of side effects. We have confirmed the efficacy of treatment with alirocumab in patients in real clinical practice there was no exacerbations of atherosclerotic cardiovascular diseases (ACVD) in patients during in the form of no exacerbations of cardiovascular diseases during the observation period (6-14 months), target low-density lipoprotein-cholesterol (LDL-C) levels were achieved in 70.0% of cases. Side effect of alirocumab was registered in one patient with a history of multiple drug allergies.